Request a copy

Full Text

• [1] Fais, S., Venturi, G., Gatenby, B., Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer and Metastasis Reviews 33 (2014), 1095–1108.
• [2] Sennoune, S.R., Luo, D., Martínez-Zaguilán, R., Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochemistry and Biophysics 40 (2004), 185–206.
• [3] Torigoe, T., Izumi, H., Ishiguchi, H., et al. Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. Journal of Biological Chemistry 277 (2002), 36534–36543.
• [4] Luciani, F., Spada, M., De Milito, A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. Journal of the National Cancer Institute 96 (2004), 1702–1713.
• [5] De Milito, A., Canese, R., Marino, M.L., et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer 127 (2010), 207–219.
• [6] Spugnini, E.P., Baldi, A., Buglioni, S., et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. Journal of Translational Medicine, 9, 2011, 221.
• [7] Ferrari, S., Perut, F., Fagioli, F., et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. Journal of Translational Medicine, 11, 2013, 268.
• [8] Brana, I., Ocana, A., Chen, E.X., et al. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Investigational New Drugs 32 (2014), 1269–1277.
• [9] Wang, B.Y., Zhang, J., Wang, J.L., et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. Journal of Experimental and Clinical Cancer Research, 34, 2015, 85.
• [10] Browder, T., Butterfield, C.E., Kräling, B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research 60 (2000), 1878–1886.
• [11] Romiti, A., Cox, M.C., Sarcina, I., et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemotherapy and Pharmacology 72 (2013), 13–33.
• [12] Roberto, M., Romiti, A., Onesti, C.E., et al. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anti-Cancer Drugs 27 (2016), 106–111.
• [13] Romiti, A., Onesti, C.E., Roberto, M., et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Medical Oncology, 32, 2015, 54.
• [14] Marchetti, P., Milano, A., D'Antonio, C., et al. Association between proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumors: a randomized phase II trial. Clinical Colorectal Cancer, 2016, 10.1016/j.clcc.2016.06.005.
• [15] Bocci, G.1., Kerbel, R.S., Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nature Reviews Clinical Oncology, 2016, 10.1038/nrclinonc.2016.64.
• [16] Grothey, A., Van Cutsem, E., Sobrero, A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
• [17] Li, J., Qin, S., Xu, R., et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 16 (2015), 619–629.